Novartis Sales Growth Tests the Pharma Patent Cliff
Novartis gave health investors a clean case study in the patent cliff problem on July 21, 2026. Sales grew again in Q2, but the route was not smooth. New medicines had to run hard just to offset copycat pressure on older blockbusters.